Jasper Therapeutics (NASDAQ:JSPR) Posts Earnings Results, Beats Estimates By $0.47 EPS

Jasper Therapeutics (NASDAQ:JSPR) released its quarterly earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.47, FiscalAI reports.

Jasper Therapeutics Trading Down 14.3%

Shares of JSPR traded down $0.15 during trading hours on Monday, reaching $0.90. The company had a trading volume of 836,334 shares, compared to its average volume of 598,227. Jasper Therapeutics has a 12-month low of $0.88 and a 12-month high of $7.19. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.79. The company has a market capitalization of $25.18 million, a price-to-earnings ratio of -0.15 and a beta of 3.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its position in shares of Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after acquiring an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $3,291,000. Velan Capital Investment Management LP grew its holdings in shares of Jasper Therapeutics by 86.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the period. Woodline Partners LP purchased a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $2,475,000. Finally, Millennium Management LLC increased its stake in Jasper Therapeutics by 194.2% in the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after purchasing an additional 708,844 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JSPR has been the subject of a number of recent research reports. UBS Group initiated coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Rodman & Renshaw started coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.88.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.